Real-world data: luspatercept may cut transfusion needs in MDS patients

NCT ID NCT07073690

Completed Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at 88 adults in China with lower-risk myelodysplastic syndromes (MDS) who had not received prior treatment with erythropoiesis-stimulating agents. They were given luspatercept, and researchers tracked how many became free from red blood cell transfusions and whether their hemoglobin levels improved. The goal was to see how the drug works in everyday medical practice.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: luspatercept
What this could lead to: If successful, this could confirm that luspatercept helps reduce or eliminate the need for blood transfusions in people with lower-risk MDS.
What could go wrong: This is a small, completed real-world study, not a large controlled trial. Results may not apply to all patients, and benefits may vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELODYSPLASTIC SYNDROMES

Contacts and locations

Locations

Zhijian Xiao

Tianjin, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.